Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Biosyent Inc V.RX

Alternate Symbol(s):  BIOYF

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.


TSXV:RX - Post by User

<< Previous
Bullboard Posts
Next >>
Post by FormerHedgieon Mar 18, 2024 4:05pm
114 Views
Post# 35939052

Simple dividend math, every $1M D/E increase = $4.48/share

Simple dividend math, every $1M D/E increase = $4.48/shareSome simple math on the impact that raising dividends could have on the stock.

Let's evaluation the impact that an $1M increase in the dividend could have.

The stock currently trades at 2.12%.  For those of you who may not know how to calculate this, here is math

2023 Dividend amoung in $1.91M (from 2023 AIF) or $0.16/share

You can calculate the dividend yield by dividing the D/E by the stock price 0.16/8.62x100=1.86%

The question then becomes, what would the stock price be if you increased the dividend and the market valued the stock holding the same relationship that the stock currently trades at.

So, if we were to increase the dividend by $1M then what would the stock do.

It would increase in price by $4.48/share.  $1M/.0186/12M (shares outstanding)

So I ask you, what would you rather have, less shares outstanding or higher dividends.

in 2023, the AIF says the company bought back 400k share.  If we assume they paid $7.50/share that was $3M spend in share buy backs. 

If the same $3M were paid to shareholders where do you think the stock would be today?  If we use the math above, every $1M increase in dividends equates to a $4.48/share increase in value.  So if the $3M was paid out, it could have added $13.44/share in value. 

Using today price, the 12 month share price change was $1.31/share ($8.59-$7.28).

CUT THE NCIB and raise the dividend!!!!!

If you like this, please LIKE my post. 


<< Previous
Bullboard Posts
Next >>